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1640differ (5). The empiric 4-graded scale used appears to
be “patient-reported”; however, it is unclear whether
the “mild, moderate, or severe physical effort”
description was clinician-directed. As the major
endpoint was “angina free,” this is of less importance
in this particular discussion. A second consideration
is the observation time course; that is, does “angina-
free at 12 months” infer no pain over the entire 12
months or no pain in the month prior to the 12-month
interval? The latter is often utilized, but it is unclear
in the present study. Finally, has the DUTCH PEERS
4-category post-PCI angina scale been validated? The
studies described previously (2–4) have utilized the
Seattle Angina Questionnaire (SAQ), which has been
shown to be reproducible in patients with stable
angina, responsive to PCI, and validated with short-
acting nitrate consumption. These characteristics
need to be detailed for the DUTCH PEERS angina scale
to assist with interpretation of the results. Further-
more, the SAQ was not used because it was too long;
however, the short version (SAQ-7) would have been
appropriate.
Thus, the future evolution of evaluating post-PCI
angina requires the use of established validated
measures as well as detailed documentation of the
patient, angiographic, and interventional factors that
may inﬂuence this important PROM. The measure-
ment of this endpoint is fundamental and should be
incorporated into all PCI studies, particularly because
it is often the primary reason the patient initially
sought medical attention.Rosanna Tavella, BSc(Hons), PhD
Isuru Ranasinghe, MBBS, MMed (Clin Epi), PhD
Chris Zeitz, MBBS, PhD
*John F. Beltrame, BSc, BMBS, PhD
*Basil Hetzel Institute for Translational Health Research
28 Woodville Road, Woodville South




Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
RE F E RENCE S
1. Sen H, Lam MK, Lowik MM, et al. Clinical events and patient-reported chest
pain in all-comers treated with Resolute Integrity and Promus Element stents:
2-year follow-up of the DUTCH PEERS (DUrable Polymer-Based STent CHal-
lenge of Promus ElemEnt Versus ReSolute Integrity) randomized trial
(TWENTE II). J Am Coll Cardiol Intv 2015;8:889–99.
2. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in
patients with stable coronary disease. N Engl J Med 2008;359:677–87.
3. Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-
eluting stents or coronary-artery bypass surgery. N Engl J Med 2011;364:
1016–26.4. Abdallah MS, Wang K, Magnuson EA, et al. Quality of life after PCI vs CABG
among patients with diabetes and multivessel coronary artery disease: a
randomized clinical trial. JAMA 2013;310:1581–90.
5. Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of
weekly angina among patients with chronic stable angina in primary care
practices: The Coronary Artery Disease in General Practice (CADENCE) Study.
Arch Intern Med 2009;169:1491–9.REPLY: Post-Percutaneous Coronary
Intervention Angina: A New Performance
Measure?We welcome the opportunity of responding to the
letter by Dr. Tavella and colleagues and expand on
the chest pain assessment in the DUTCH PEERS (DU-
rable polymer-based sTent CHallenge of Promus
ElemEnt versus ReSolute Integrity; TWENTE II) study
(1). As a matter of fact, the pain score used is
straightforward and leans on routine clinical practice.
Patients were asked whether they still experienced
chest pain (referring to the last few weeks) and to
individually grade the level of physical activity when
having pain. This approach reﬂects that, for many
patients, it is most important to be symptom-free
during ordinary activities, because this ensures an
independent, self-determined life. The majority of
patients provided the information through a postal
questionnaire, whereas a telephone follow-up (same
questions) and/or consultation of medical records
was performed in much lower proportions of patients.
Hence, it is fair to address these data as patient-
reported.
The short version of the well-deﬁned and validated
Seattle Angina Questionnaire (SAQ), the SAQ-7, may
certainly be an interesting instrument to assess
angina and its consequences, but it still comprises 7
questions (2). Because the PAPAYA (PAtient Prefer-
ence Analysis of Yearly follow-up After PCI) study
recently revealed that patients prefer #6 to 10 follow-
up questions (3), and aspects other than chest pain/
angina need to be addressed (e.g., adverse events,
hospitalization, medication), SAQ-7 may still be
borderline large for use in all-comer studies.
The chest pain score in DUTCH PEERS is very short,
simple, and related to the patient’s individual ﬁt-
ness and performance. It does not measure angina
but rather evaluates patient-reported chest pain,
which is—albeit not exclusively—a key symptom of
angina. There was no distinction between typical and
atypical chest pain because both affect the patient’s
performance, may trigger further cardiac assess-
ment, and increase the costs of medical care. Because
the approach used in the DUTCH PEERS study
was not validated against antianginal medication,
a comparison with the SAQ might seem appealing.
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1641However, recently reported data from the ABSORB II
study (ABSORB II Randomized Controlled Trial)
demonstrated that the results of angina evaluation
based on the SAQ can differ quite signiﬁcantly from
site-diagnosed angina/chest pain. Nonetheless, the
investigators considered the latter a clinically valu-
able parameter and reported it in detail (4).
Although we recognize certain limitations of our
straightforward approach of chest pain assessment,
we feel that the data obtained are of interest and
presume that they are clinically meaningful.*Clemens von Birgelen, MD, PhD
Liefke C. van der Heijden, MD
Hanim Sen, MD, PhD
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Embolization for Weight LossObesity is associated with adverse cardiovascular and
metabolic conditions. Dietary, medical, or surgical
weight loss strategies are frequently unsuccessful and
accompanied by risks. Although many appetite-
limiting hormones have been discovered, only 1 hor-
mone, ghrelin, has been shown to be orexigenic
(appetite stimulating) (1). Ghrelin-producing cells are
located in the fundus of the stomach; through ghrelin
secretion, these cells stimulate appetite, resulting in
weight gain (1). Several animal studies have shown
that embolization of arteries supplying the gastric
fundus reduces serum ghrelin levels and food intake
(2–4). In addition, signiﬁcant weight loss has been
demonstrated in humans after left gastric artery
embolization to treat active upper gastrointestinal
bleeding (5). The aim of this prospective, single-armft Gastric Artery
Contrast injection outlines the celiac trunk (CT), common hepatic
tive left gastric artery angiography. A microcatheter (MC) has been
artery for support. (C) Selective angiography of the left gastric artery.
ted (arrows).
